Head to Head Analysis: MacroGenics (MGNX) & Its Competitors

MacroGenics (NASDAQ:MGNX) is one of 847 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare MacroGenics to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.

Profitability

This table compares MacroGenics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
MacroGenics Competitors	-9,046.42%	-198.98%	-30.68%

Analyst Ratings

This is a summary of current ratings and recommmendations for MacroGenics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1	2	3	0	2.33
MacroGenics Competitors	9766	14999	45307	1578	2.54

MacroGenics presently has a consensus target price of $6.33, suggesting a potential upside of 157.14%. As a group, “Biotechnology” companies have a potential upside of 91.55%. Given MacroGenics’ higher probable upside, research analysts plainly believe MacroGenics is more favorable than its rivals.

Volatility and Risk

MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, MacroGenics’ rivals have a beta of 1.12, suggesting that their average share price is 12% more volatile than the S&P 500.

Valuation & Earnings

This table compares MacroGenics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MacroGenics	$175.14 million	-$74.62 million	-11.20
MacroGenics Competitors	$695.88 million	$9.64 million	-9.99

MacroGenics’ rivals have higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

MacroGenics beats its rivals on 7 of the 13 factors compared.

About MacroGenics

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.